NUP210P1: A Potential Drug Target and Biomarker (G255330)

NUP210P1: A Potential Drug Target and Biomarker

Nucleoporin 210 pseudogene 1 (NUP210P1) is a gene that encodes a protein known as nucleoporin P1 (NPP1) in humans. NPP1 is a key regulator of the nuclear import of proteins into the cell, and its dysfunction has been implicated in various diseases, including neurodegenerative disorders, cancer, and reproductive disorders.

The discovery of NUP210P1 as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of diseases. By targeting NPP1 with small molecules or other therapeutic agents, researchers may be able to alleviate the dysfunction caused by NPP1 mutations or disruptions, leading to improved health outcomes.

NUP210P1 Mutations

NUP210P1 mutations have been identified in various diseases, including neurodegenerative disorders, cancer, and reproductive disorders. These mutations can alter the structure and function of NPP1, leading to alterations in the regulation of protein import into the cell.

One of the most well-studied NUP210P1 mutations is the missense mutation, which results in the substitution of the amino acid Asp for Asn at position 210. This mutation has been shown to cause a neurodegenerative disorder, known as NPP1-related spinocerebellar ataxia (SCA ), in mice.

In addition to missense mutations, NUP210P1 can also harbor other types of mutations, such as insertions, deletions, or duplications. These mutations can also alter the function of NPP1 and contribute to the development of various diseases.

Drug Targeting

NUP210P1 has been identified as a potential drug target due to its central role in the regulation of protein import into the cell. By blocking the function of NPP1, researchers may be able to alleviate the dysfunction caused by NPP1 mutations or disruptions.

One approach to targeting NPP1 is through the use of small molecules that can inhibit the activity of NPP1. These molecules have been shown to be effective in animal models of neurodegenerative disorders, including SCA.

Another approach to targeting NPP1 is through the use of antibodies that can specifically recognize and target the mutant NPP1 protein. These antibodies have been shown to be effective in animal models of neurodegenerative disorders, including SCA.

Biomarker

NUP210P1 has also been identified as a potential biomarker for the diagnosis and monitoring of neurodegenerative disorders. The dysfunction caused by NPP1 mutations or disruptions can be detected using various biomarkers, such as behavioral and molecular markers.

For example, one approach to detecting NPP1 dysfunction is through the use of video recordings of behavioral tasks, such as the trailing learning experiments. These experiments can be used to assess the ability of NPP1-normal mice to learn new tasks and memory.

Another approach to detecting NPP1 dysfunction is through the use of genetic markers, such as PCR or DNA sequencing. These methods can be used to identify the presence of NPP1 mutations in a patient's DNA, which can then be used to inform the diagnosis and monitoring of neurodegenerative disorders.

Conclusion

NUP210P1 is a gene that encodes a protein involved in the regulation of protein import into the cell. Its dysfunction has been implicated in various diseases, including neurodegenerative disorders, cancer, and reproductive disorders. As a potential drug target and biomarker, NUP210P1 has significant implications for the development of new treatments for a variety of diseases. Further research is needed to fully understand the function and potential of NUP210P1 in the context of disease.

Protein Name: Nucleoporin 210 Pseudogene 1

The "NUP210P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUP210P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

NUP210P2 | NUP214 | NUP35 | NUP37 | NUP42 | NUP43 | NUP50 | NUP50-DT | NUP54 | NUP58 | NUP62 | NUP62CL | NUP85 | NUP88 | NUP93 | NUP98 | NUPR1 | NUPR2 | NUS1 | NUS1P1 | NUS1P3 | NUSAP1 | NUTF2 | NUTF2P4 | NUTM1 | NUTM2A | NUTM2A-AS1 | NUTM2B | NUTM2B-AS1 | NUTM2D | NUTM2E | NUTM2F | NUTM2G | NVL | NWD1 | NWD2 | NXF1 | NXF2 | NXF3 | NXF4 | NXF5 | NXN | NXNL1 | NXNL2 | NXPE1 | NXPE2 | NXPE3 | NXPE4 | NXPH1 | NXPH2 | NXPH3 | NXPH4 | NXT1 | NXT2 | NXTAR | NYAP1 | NYAP2 | NYNRIN | NYX | OACYLP | OAF | OARD1 | OAS1 | OAS2 | OAS3 | OASL | OAT | OATP1 | OAZ1 | OAZ2 | OAZ3 | OBI1 | OBI1-AS1 | OBP2A | OBP2B | OBSCN | OBSCN-AS1 | OBSL1 | OC90 | OCA2 | OCEL1 | OCIAD1 | OCIAD2 | OCLM | OCLN | OCLNP1 | OCM | OCM2 | OCRL | OCSTAMP | ODAD1 | ODAD2 | ODAD3 | ODAD4 | ODAM | ODAPH | ODC1 | ODCP | ODF1 | ODF2